Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$122.18
neg -1.20
-0.95%
Today's Range: 121.55 - 123.14 | CELG Avg Daily Volume: 5,648,500
Last Update: 02/27/15 - 11:51 AM EST
Volume: 1,195,813
YTD Performance: 10.27%
Open: $122.81
Previous Close: $123.35
52 Week Range: $66.85 - $125.45
Oustanding Shares: 800,590,656
Market Cap: 98,552,709,754
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 15 14 16 16
Moderate Buy 1 1 1 1
Hold 4 4 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.45 1.47 1.26 1.26
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 51.51
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
51.51 51.50 26.73
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.54% 54.21% 229.42%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $0.90 $1.03 $4.32 $6.09
Number of Analysts 3 3 3 3
High Estimate $0.93 $1.12 $4.47 $7.21
Low Estimate $0.87 $0.98 $4.23 $5.45
Prior Year $0.73 $0.80 $3.36 $4.32
Growth Rate (Year over Year) 23.29% 29.17% 28.57% 40.97%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateRBC Healthcare Conf.

Feb 24, 2015 | 6:51 AM EST

RBC Healthcare Conference

By

Robert Moreno

 | Feb 19, 2015 | 2:10 PM EST

Chart setups in Celgene, Medivation and AMAG Pharmaceuticals.

By

Jim Cramer

 | Feb 19, 2015 | 11:02 AM EST

Watch this leadership group that's been lagging.

bullishCelgene rated new Buy at Canaccord

Feb 18, 2015 | 6:55 AM EST

CELG was initiated with a Buy rating, Canaccord Genuity said. $156 price target. Revlimid should drive growth in the next several quarters. 

By

Jim Cramer

 | Feb 4, 2015 | 2:06 PM EST

The 'dead bodies' are adding up.

By

James "Rev Shark" DePorre

 | Feb 3, 2015 | 4:13 PM EST

For traders? Not so much.

By

Bret Jensen

 | Feb 2, 2015 | 10:01 AM EST
Trading in February has commenced and indices started up, but have already given all of their early gains. Americans boosted their savings in December and cut spending by the largest amount in five years.
By

Bret Jensen

 | Jan 29, 2015 | 9:46 AM EST

I am adding allocation to healthcare.

By

Timothy Collins

 | Jan 28, 2015 | 2:53 PM EST

I don't foresee this announcement as a driver of equities.

By

Jim Cramer

 | Jan 15, 2015 | 3:40 PM EST

Use the overall weakness to pick up the America First stocks.

AAPL Watch to contain technology that will eventually unlock your car/replace your keys

VIX is stuck with very steep skew keeping the index elevated. Until the skew in SPX start...
Ingram Micro (IM) is cheap today after reporting good earnings, although they were hurt by...
....but does every stock need to follow? In a low-correlation, stockpicker's market the a...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.